Table of Contents - Espicom

More documents

Recommendations

Info

Table of Contents x © Espicom Business Intelligence © 2012 UBM Semiconductor Insights Diabetes Landscape: 7.1 LIST OF ABBREVIATIONS ......................................................................................................................................................246 7.2 - REPORT METHODOLOGY .................................................................................................................................................. 247 Sources ................................................................................................................................................................................247 Market forecasts ................................................................................................................................................................ 248 VOLUME II - DIABETES TECHNOLOGY AND INTELLECTUAL PROPERTY ANALYSIS 1.0 SUMMARY ............................................................................................................................................... 251 Figure 1.1 – Diabetes Landscape by Technology........................................................................................................................................................................................ 252 Figure 1.2 – High Level Overview of Diabetes Patent Activity ...................................................................................................................................................................254 Figure 1.3 – Bar Chart of Totals for each Technology Group ...................................................................................................................................................................... 255 Figure 1.4 – Top 20 Assignees Patents from this Study .............................................................................................................................................................................. 256 Figure 1.5 - Blood Extraction by Priority Date by Assignee ........................................................................................................................................................................ 257 Figure 1.6 – Number of Patents versus Revenue for Highlighted Companies ...........................................................................................................................................258 Figure 1.7 – Litigation Analysis .................................................................................................................................................................................................................. 259 Table 1.1 – Table of Highlighted Companies and Technologies .................................................................................................................................................................260 2.0 INTRODUCTION ...................................................................................................................................... 262 3.0 TECHNOLOGY ......................................................................................................................................... 264 Figure 3.1 – Diabetes Landscape by Technology ....................................................................................................................................................................................... 265 Figure 3.2 – Self Monitoring of Blood Glucose ...........................................................................................................................................................................................266 Figure 3.3 – Blood Glucose Test Strip Operation ........................................................................................................................................................................................ 267 Figure 3.4 – Continuous Glucose Monitoring (CGM) .................................................................................................................................................................................. 267 Figure 3.5 – Artificial Pancreas Representative Diagram .......................................................................................................................................................................... 269 4.0 OVERVIEW OF PATENT ACTIVITIES ....................................................................................................... 270 Figure 4.1 – High Level Overview of Diabetes Patent Activity ................................................................................................................................................................... 271 4.1 Analysis of Patents Sorted by this Study .......................................................................................................................... 273 Figure 4.2 – Bar Chart of Totals for each Technology Group...................................................................................................................................................................... 273 Figure 4.3 – Top 20 Assignees Patents from This Study ............................................................................................................................................................................. 274 Figure 4.4 – Patents by Priority Date ......................................................................................................................................................................................................... 275 Figure 4.5 – Priority Date by Top 5 Companies .......................................................................................................................................................................................... 276 Figure 4.6 – Patents by Published Date .....................................................................................................................................................................................................277 Figure 4.7 – Patents by Source Jurisdiction ............................................................................................................................................................................................... 278 Figure 4.8 – Top 10 IPC Codes from the Patents Analyzed ......................................................................................................................................................................... 279 Figure 4.9 – Total U.S. Patents by Assignee ...............................................................................................................................................................................................280 Figure 4.10 – USP Classification Analysis within the U.S. Dataset ............................................................................................................................................................. 281 5.0 PATENT ANALYSIS BY TECHNOLOGY SUBCATEGORY ......................................................................... 282 5.1 Detection and Monitoring – Periodic – Invasive – Blood Extraction ..........................................................................283 Figure 5.1 – Blood Extraction – Top Assignees ..........................................................................................................................................................................................283 Priority Date by Year and Source: ...................................................................................................................................................... 284 Figure 5.2 - Blood Extraction by Priority Date ............................................................................................................................................................................................284 Priority Date by Year by Top 5 Assignees within the Subcategory: ............................................................................................ 285 Figure 5.3 - Blood Extraction by Priority Date by Assignee ........................................................................................................................................................................ 285 Published Date by Year and Source: ................................................................................................................................................. 286 Figure 5.4 - Blood Extraction by Published Date ........................................................................................................................................................................................286 IPC Analysis – Top 10 Codes: ............................................................................................................................................................... 287 Figure 5.5 - Blood Extraction by IPC Code .................................................................................................................................................................................................. 287 USPC Analysis – Top 10 Codes: ........................................................................................................................................................... 288 Figure 5.6 - Blood Extraction by USPC Code ...............................................................................................................................................................................................288 Figure 5.7 – Blood Extraction - Text Clustering Analysis ...........................................................................................................................................................................289 Source Jurisdiction: .............................................................................................................................................................................. 290 Figure 5.8 - Blood Extraction by Source Jurisdiction ..................................................................................................................................................................................290 Top Patents ............................................................................................................................................................................................ 291 Table 5.1 - Top Patents Identified in the Blood Extraction Group ............................................................................................................................................................... 291 May 2012
Diabetes Landscape: May 2012 © Espicom Business Intelligence © 2012 UBM Semiconductor Insights Table of Contents US6461496B1: Abbott Laboratories ................................................................................................................................292 Figure 5.9 – Representative Image in US6461496 ..................................................................................................................................................................................... 292 Figure 5.10 – Top 20 Companies Citing US6461496 .................................................................................................................................................................................. 293 US5916230A: Bayer AG .................................................................................................................................................... 294 Figure 5.11 – Representative Images of US5916230 ..................................................................................................................................................................................294 Figure 5.12 – Top 20 Companies Citing US5916230 ................................................................................................................................................................................... 295 5.2 Detection and Monitoring – Periodic – Invasive – Test Strips ......................................................................................296 Figure 5.13 – Test Strips – Top Assignees ...................................................................................................................................................................................................296 Priority Date by Year and Source: ...................................................................................................................................................... 297 Figure 5.14 - Test Strips by Priority Date ..................................................................................................................................................................................................... 297 Priority Date by Year by Assignee: .................................................................................................................................................... 297 Figure 5.15 - Test Strips by Priority Date by Assignee ................................................................................................................................................................................. 297 Published Date by Year: ...................................................................................................................................................................... 298 Figure 5.16 - Test Strips by Published Date .................................................................................................................................................................................................298 IPC Analysis – Top 10 Codes: ............................................................................................................................................................... 299 Figure 5.17 - Test Strips by IPC Code ............................................................................................................................................................................................................299 USPC Analysis – Top 10 Codes: ........................................................................................................................................................... 300 Figure 5.18 - Test Strips by USPC Code ........................................................................................................................................................................................................300 Text Clustering Analysis: ..................................................................................................................................................................... 301 Figure 5.19 – Test Strips - Text Clustering Analysis ..................................................................................................................................................................................... 301 Source Jurisdiction: .............................................................................................................................................................................. 302 Figure 5.20 - Test Strips by Source Jurisdiction ...........................................................................................................................................................................................302 Top Patents ............................................................................................................................................................................................ 303 Table 5.2 - Top Patents Identified in the Test Strips Group .........................................................................................................................................................................303 US5496453A: Arkray, Inc. ................................................................................................................................................ 304 Figure 5.21 – Representative Image in US5496453 ...................................................................................................................................................................................304 Figure 5.22 – Top 20 Companies Citing US5496453 ..................................................................................................................................................................................305 US5563042: Johnson & Johnson ...................................................................................................................................... 306 Figure 5.23 – Representative Image in US5563042 ...................................................................................................................................................................................306 Figure 5.24 – Top 20 Companies Citing US5563042 ..................................................................................................................................................................................307 5.3 Detection and Monitoring – Periodic – Invasive – Devices ..........................................................................................308 Figure 5.25 – Devices – Top Assignees ......................................................................................................................................................................................................308 Priority Date by Year: ........................................................................................................................................................................... 309 Figure 5.26 - Devices by Priority Date .........................................................................................................................................................................................................309 Priority Date by Year by Assignee: .................................................................................................................................................... 309 Figure 5.27 - Devices by Priority Date by Assignee .....................................................................................................................................................................................309 Published Date by Year and Source: ..................................................................................................................................................310 Figure 5.28 - Devices by Published Date ..................................................................................................................................................................................................... 310 IPC Analysis – Top 10 Codes: ................................................................................................................................................................311 Figure 5.29 - Devices by IPC Code ................................................................................................................................................................................................................311 USPC Analysis – Top 10 Codes: ............................................................................................................................................................312 Figure 5.30 - Devices by USPC Code ............................................................................................................................................................................................................ 312 Text Clustering Analysis: ......................................................................................................................................................................313 Figure 5.31 – Devices - Text Clustering Analysis ......................................................................................................................................................................................... 313 Source Jurisdiction: ...............................................................................................................................................................................314 Figure 5.32 - Devices by Source Jurisdiction ............................................................................................................................................................................................... 314 Top Patents .............................................................................................................................................................................................315 Table 5.3 - Top Patents Identified in the Devices Group ............................................................................................................................................................................. 315 US6233471: Johnson & Johnson ......................................................................................................................................316 Figure 5.33 – Representative Image in US6233471 ................................................................................................................................................................................... 316 Figure 5.34 – Top 20 Companies Citing US6233471 .................................................................................................................................................................................. 317 5.4 Detection and Monitoring – Periodic – Minimally Invasive – Interstitial Fluid ......................................................... 318 Figure 5.35 – Interstitial Fluid – Top Assignees ......................................................................................................................................................................................... 318 Priority Date by Year: ............................................................................................................................................................................319 Figure 5.36 - Interstitial Fluid by Priority Date ........................................................................................................................................................................................... 319 xi
Page 1 and 2: DIABETES LANDSCAPE Market, Technolo
Page 3 and 4: Diabetes Landscape: CONTENTS Table
Page 5 and 6: Diabetes Landscape: May 2012 © Esp
Page 9: Diabetes Landscape: May 2012 © Esp
Page 17 and 18: Diabetes Landscape: Table of Conten

Table of Contents - Espicom

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?